Modelling the end of a Zero-COVID strategy using nirmatrelvir/ritonavir, vaccination and NPIs in Wallis and FutunaResearch in context
Summary: Background: Ending Zero-COVID is challenging, particularly when vaccine coverage is low. Considering Wallis and Futuna, a French Zero-COVID territory affected by reluctance to vaccination, low immunity and high levels of comorbidities, we investigate how targeted use of nirmatrelvir/ritona...
Main Authors: | Antoine Brault, Cécile Tran-Kiem, Clément Couteaux, Valérie Olié, Juliette Paireau, Yazdan Yazdanpanah, Jade Ghosn, Guillaume Martin-Blondel, Paolo Bosetti, Simon Cauchemez |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-01-01
|
Series: | The Lancet Regional Health. Western Pacific |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2666606522002498 |
Similar Items
-
Clinical Effectiveness of Ritonavir-Boosted Nirmatrelvir—A Literature Review
by: Sydney Paltra, et al.
Published: (2024-01-01) -
Oral Antiviral Treatment for COVID-19: A Comprehensive Review on Nirmatrelvir/Ritonavir
by: Karolina Akinosoglou, et al.
Published: (2022-11-01) -
Oral Nirmatrelvir/Ritonavir Therapy for COVID-19: The Dawn in the Dark?
by: Yuan-Pin Hung, et al.
Published: (2022-02-01) -
Case report: Supratherapeutic tacrolimus concentrations with nirmatrelvir/ritonavir in a lung transplant patient: a case report using Rifampin for reversal
by: Yu Xiong, et al.
Published: (2023-11-01) -
Overview of Drug-Drug Interactions Between Ritonavir-Boosted Nirmatrelvir (Paxlovid) and Targeted Therapy and Supportive Care for Lung Cancer
by: Kaleem Anwar, PharmD, et al.
Published: (2023-02-01)